摘要
目的：比较40 mg与10 mg阿托伐他汀对急性缺血性脑卒中血清内皮素-1（ET-1）及血栓素B2（TXB2）的影响。方法选取2009年3月~2011年10月在本院确诊的83例急性缺血性脑卒中患者作为研究对象，随机分为阿托伐他汀10 mg/d治疗组（41例）及40 mg/d治疗组（42例）。比较两组治疗前后的血清ET-1及TXB2水平。随访4周，记录不良反应发生率。结果40 mg治疗组治疗后的血清ET-1、TXB2水平显著低于10 mg治疗组治疗后，差异有统计学意义（P〈0.05）。两组在随访期间无横纹肌溶解及药物性肝炎发生，两组的不良反应发生率比较，差异无统计学意义（P〉0.05）。结论40 mg阿托伐他汀能够降低急性缺血性脑卒中患者的血清ET-1、TXB2水平且不良反应发生率无明显增高。
Objective To compare the 40 mg and 10 mg of atorvastatin on serum endothelin-1 （ET-1） and thrombox-ane B2 （TXB2） in patients with acute ischemic stroke. Methods 83 cases with acute ischemic stroke from March 2009 to October 2011 in our hospital were selected and randomly divided into the 10 mg group of atorvastatin （41 cases ） and the 40 mg group of atorvastatin （42 cases）.The level of serum ET-1 and TXB2 in two groups before and after treatment was compared respectively.The follow-up period of 4 weeks,the incidence of adverse reaction was recorded. Results The level of serum ET-1 and TXB2 in the 40 mg group of atorvastatin after treatment was lower than that in the 10 mg group of atorvastatin after treatment,with significant difference （P〈0.05）.There was no rhabdomyolysis and drug-induced liver disease during the follow-up period.The incidence of adverse reaction in two groups was not statistically signifi-cant （P〉0.05）. Conclusion 40 mg atorvastatin can reduce the serum levels of ET-1 and TXB2 in patients with acute is-chemic stroke,and the incidence of adverse reaction is not significantly higher.
出处
《中国当代医药》
2015年第16期150-152,共3页
China Modern Medicine
基金
广东省广州市医药卫生科技项目(2009-YB-186)
